Clinical utility of genotypic resistance tests for HIV-1-infected patients with low-level virological failure.

Journal of Clinical Microbiology
A ElgalibC Y W Tong

Abstract

The usefulness of genotypic resistance tests (GRT) among HIV-1 patients with low-level virological failure (LLVF) was evaluated. Up to 78% of samples with <1,000 copies/ml were sequenced successfully. For samples with 50 to 200 copies/ml, the success rate was as high as 69%. LLVF should not deter clinicians from requesting GRT.

References

May 26, 2004·Journal of Virological Methods·Nicola MackieJohn R Clarke
Sep 8, 2005·Journal of Clinical Microbiology·C Y W TongI L Chrystie
Aug 4, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Yumi MitsuyaRobert W Shafer
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA
Oct 2, 2008·HIV Medicine·B G GazzardUNKNOWN BHIVA Treatment Guidelines Writing Group

❮ Previous
Next ❯

Citations

Feb 9, 2012·The Indian Journal of Medical Research·Madhu Vajpayee, Teena Mohan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.